Larotrectinib Efficacy in Infant-Type Hemispheric Glioma with NTRK Fusion

Larotrectinib successfully treated an infant with an infant-type hemispheric glioma (ITHG) harboring an NTRK fusion, according to a case report published in Cureus. The targeted therapy led to a significant reduction in tumor size and improvement in clinical symptoms, providing a precision medicine alternative for a rare pediatric brain tumor that often resists conventional treatment.

Infant-type hemispheric gliomas are aggressive tumors occurring in children under one year of age. These tumors typically present as large masses in one hemisphere of the brain, often causing severe neurological deficits and developmental delays. According to the Cureus report, these neoplasms are characterized by specific genetic alterations, including fusions involving the Neurotrophic Tyrosine Receptor Kinase (NTRK) genes.

The reported case involved an infant diagnosed with ITHG. Molecular testing identified an NTRK fusion, a genetic driver that causes the NTRK protein to be constitutively active, which in turn promotes uncontrolled cell growth and tumor progression. Based on this genetic profile, clinicians administered larotrectinib, a selective TRK inhibitor designed to block the signaling pathways activated by these fusions.

Following the administration of larotrectinib, the patient showed a positive response. Imaging revealed a decrease in the volume of the hemispheric glioma, and the patient experienced a corresponding improvement in neurological function. The report highlights that the drug’s ability to target the specific molecular driver of the tumor allowed for a more effective intervention than broad-spectrum chemotherapy.

The Role of NTRK Fusions in Pediatric Gliomas

NTRK fusions occur when an NTRK gene fuses with another gene, creating a chimeric protein that stays “on” regardless of external signals. According to the Cureus publication, these fusions are found in a subset of ITHG cases. When present, they serve as “driver mutations,” meaning they are primarily responsible for the tumor’s growth.

Larotrectinib is a “tumor-agnostic” therapy, meaning it is approved for use in various cancer types regardless of where the tumor is located in the body, provided the NTRK fusion is present. By binding to the ATP-binding site of the TRK kinase domain, the medication prevents the phosphorylation and subsequent activation of downstream signaling pathways that drive malignancy.

Clinical Challenges of Infant-Type Hemispheric Gliomas

ITHG differs from other pediatric gliomas in both its genetic makeup and its clinical behavior. Because these tumors appear in the first year of life and often occupy a large portion of a brain hemisphere, surgical resection is frequently incomplete or impossible without causing permanent, severe neurological damage.

Conventional treatments, such as radiation and standard chemotherapy, are often avoided or limited in infants due to the risk of interfering with rapid brain development. The Cureus report indicates that targeted therapies like larotrectinib offer a way to manage the disease with potentially fewer systemic side effects than traditional cytotoxic drugs.

Implications for Precision Pediatrics

The response of this patient to larotrectinib underscores the importance of early molecular profiling in pediatric oncology. Identifying the specific genetic driver of a tumor allows physicians to move away from a one-size-fits-all approach toward precision medicine.

While the reported outcome was positive, the Cureus case study emphasizes that the durability of the response and the long-term effects of TRK inhibition in developing infant brains require further study. The medical community continues to monitor how these targeted therapies impact long-term cognitive and motor development in pediatric patients.